Cyclic GMP-specific phosphodiesterase inhibitors

Patent 5981527 Issued on November 9, 1999. Estimated Expiration Date:

May 15, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3644384

3717638

3917599

Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
Patent #: 4188390
Issued on: 02/12/1980
Inventor: Campbell

Quinoline therapeutic agents
Patent #: 4686228
Issued on: 08/11/1987
Inventor: Campbell , et al.

Vaso-active medicament to treat impotence
Patent #: 5145852
Issued on: 09/08/1992
Inventor: Virag

Method of treating impotence Patent #: 5270323
Issued on: 12/14/1993
Inventor: Milne, Jr., et al.

Inventors

Application

No. 000192 filed on 05/15/1998

US Classes:

514/250, At least three rings in the polycyclo ring system544/343Tetracyclo ring system having the diazine ring as one of the cyclos (e.g., benzophenazines, etc.)

Examiners

Primary: Shah, Mukund J.
Assistant: Rao, Deepak

Attorney, Agent or Firm

Marshall, O'Toole, Gerstein, Murray & Borun

Foreign Patent References

0 357 122 EP 03/13/1990
0 362 555 EP 04/13/1990
459 666 EP 12/13/1991
463 756 EP 01/13/1992
526 004 EP 02/13/1993
03044324 JP 02/13/1991
1454171 GB 10/13/1976
1 454 171 GB 10/13/1976
WO 89/10123 WO 11/13/1989
WO 94/05661 WO 03/13/1994
WO 94/28902 WO 12/13/1994
WO 95/19978 WO 07/13/1995

International Classes

C07D 471/14
A61K 031/395

Foreign Application Priority Data

1995-07-14 GB

Abstract

A compound having the formula (I) ##STR1## and solvates thereof, wherein: R0 represents hydrogen, halogen or C1-6 alkyl;R1 represents hydrogen or C1-6 alkyl;R2 represents the bicyclic ring ##STR2## which may be optionally substituted by one or more groups selected from halogen and C1-3 alkyl; andR3 represents hydrogen or C1-3 alkyl is disclosed.The compounds are potent and selective inhibitors of cGMP-specific PDE, and are useful in a variety of therapeutic areas where such inhibition is beneficial.

Other References

E. McMahon et al., J. Pharmacol. Exp. Thera., (1989), 251, 1000-1005
F. Holmquist et al., Acta Physiol. Scand., (1991), 143, 299-304
G. Barbanti, Urol. Res., (1988), 16, 299-302
L. Ignarro et al., Biochem. and Biophys. Res. Comm., (1990), 170(2), 843-850
J. Krall et al., Bio. Reprod., (1988), 39, 913-922
M. Wilkins et al., Proc. Natl. Acad. Sci., USA, (1990, Aug.), 87, 6465-6469
M. Wilkins et al., J. Clin. Invest., (1990, Apr.), 85, 1274-1279
J. Rajfer, N. Eng. J. Med., (1992, Jan.), 326(2), 90-94
H. Knispel, Urol. Res., (1992), 20, 253-257
G. Gwinup, Annals. of Internal Medicine, (1988, Jul.), 162-163
A. Zorgniotti, J. Urol., (1992, Apr.), 147(4), 308A
K. Azadozoi et al., J. Urol., (1992, Nov.), 148, 1587-1591
K. Azadozoi et al., J. Urol., (1992, Jan.), 147, 220-225
C. Sparwasser et al., J. Urol., (1994, Dec.), 152, 2159-2163
T. Lue, "Campbell's Urology," 6th Ed., Chap. 16, P. Walsh et al., Eds., W.B. Saunders Co., 709-728 (1991)
N. Kim et al., J. Clin. Invest., (1991), 88, 112-118
S. Francis et al., in J. Beavo et al. eds. "Cyclic Nucleotide PDEs," Ch. 5 (1990) 117-140
R. Weishaar et al., J. Med. Chem., (1985), 28:5, 537-542
H. Ahn et al., Biochem. Pharmacol., (1989), 39:19, 3331-3339
C. Lugnier et al., Biochem. Pharmacol., (1986), 35:10, 1743-1751
J. Doremieux et al., Ann. Urol. Paris, (1987), 21(6), 429-434
D. Green et al., Geriatics, (1993, Jan.), 48(1), 46-58
M. Webster et al., Hematol. Oncol. Cl. of N. Am., (1990, Feb.), 4(1), 265-289
F. Holmquist et al., Acta. Physiol. Scand., (1991), 141, 441-442
J. Taher et al., J. Urol., (1993, Apr.), 149, 285A
S. Uckert et al., J. Urology., 151(5 Suppl), p. 495A (1994)
W. Aronson et al., J. Urol., (1991), 145 (4 Supp.), 341A
P. Bush et al., Fed. Am. Soc. Exp. Biol., (1991), 5(4), 175
P. Bush et al., Fed. Am. Soc. Exp. Biol., (1992), 6(4), 2092
W. Aronson et al., J. Urol., (1992), 147 (4 Supp.), 454A
P. Bush et al., Circulation, (1993, May), 87 Supp. V, V-30-V-32
R. Pickard et al., J. Urol., (1993, May) 149 (4 Supp.), 245A
R. Pickard et al., Clin. Pharmacol., (1993, Jan.), 35(5), 536P-537P
F. Trigo-Rocha et al., J. Urol., (1993, Apr.), 149, 872-877
M. Krupp et al., J. Cardiovas. Pharmacol., (1989), 13 (Supp. 2), S11-S19
"Physicians' Desk Reference," (1992), 683,1099-1100, 1344, 1941-1943
R. Morales et al., World J. Urol., (1990), 8, 80-83
J. Cortijo, Br. J. Pharmacol., (1993, Feb.), 108(2), 562-568
E. Kim et al., J. Urol., (1995), 153, 361-365
S. Korenman et al., JAGS, (1993, Apr.), 41(4), 363-366
K. Allenby et al., Angiology, (1991), 42, 418-420
H. Hamilton et al., J. Med. Chem., (1987), 30, 91-96
H. Padma-Nathan et al., Sem. in Urol., (1986, Nov.), vol. IV, No. 4, 236-238
J. Beavo et al., TiPS, (1990, Apr.), 11, 150-155
S. Korenman et al., Clin. Res., (1988), 36, 123A
D. Halsted et al., J. Urol., (1986, Jul.), 136, 109-110
W. Thompson, Pharmac. Ther., (1991), 51, 13-33
M. Giembycz et al., Clin. and Exper. Allergy, (1992), 22, 337-344
C. Nicholson et al., TIPS, (1991, Jan.), 12, 19-27
J. LeBlanc et al., Eur. J. Cardiothorac Surg., (1993), 7, 211-215
C. Stief et al., J. Urol., (1992, Nov.), 148, 1437-1440
C. Stief et al., World J. Urol., (1991), 9, 237-239
C. Clyne et al., Br. J. Surg., (1987, Apr.), 74, 246-248
V. Mirone et al., Acta. Urol. Ltd., (1992), Suppl. 4, 11-12
P. Bush, Ph.D. Thesis (1992), pp. 159-160
T. Lincoln, Pharmac. Ther., (1989), 41, 479-502
J. Heaton et al., Urology, (Feb. 1995), 45(2), 200-206
A. Bowman et al., Br. J. Pharmac., (1984), 81, 665-674
F. Trigo-Rocha et al., Am. J. Physiol., (1993, Feb.), 164, H419-H422
J. Reiser et al., Br. J. Dis. Chest, (1986), 80, 157-163
P. Bush et al., J. Urol., (1992, Jun.), 147, 1650-1655
F. Holmquist et al., J. Urol. (1993, Oct.), 150, 1310-1315
R. Rudd et al., Br. J. Dis. Chest, (1983), 77, 78-86
Beyer et al., Phys. and Behav., (1981), 27, 731-733
Pickard et al., Br. J. Pharmacol., (1991), 104 755-759
Martinez-Pineiro et al., Eur. Urol., (1993), 24, 492-499
Mirone et al., Br. J. Urol., (Mar., 1993), 71(3), 365
Murray et al., Biochemical Soc. Trans., (1992), 20, 460-464
Raeburn et al., Prog. Drug. Res., (1993), 12-32
Merkel, Cardio Drug. Rev., (1993), 11(4), 501-515
"Physicians' Desk Reference," (1992) 2207-2208
Cimino et al., Biochem. Pharmacology, (1988), 37(14), 2739-2745
Watanabe et al., Federation Proceedings, (1982), 41(7), 2292-2399
Earl et al., Life Sciences, (1984), 35, 525-534
Brindley, Brit. J. Phychiat., (1983), 143, 332-337
Keogh, Aust. NZ. J. Med., (1989), 19, 108-112
Funderbunk, New Engl. J. Med., (1974), 290, 630-631
Beretta, Acta European Fertilitatis, (1986), 17, 43-45
"Physicians' Desk Reference," (1992), 1778-1779
Hess in "Prazosin: Evaluation of a New Antihypertensive Agent," D. Cotton ed., American Elsevier, NY, (1974), 3-15
Dadkar et al., Ind. J. Exp. Biol., (1982), 20, 484-487
D'Armiento et al., Eur. J. Pharmacol., (1980), 65, 234-247
Bhalla et al., Brit. Med. J., (1979), 2, 1059
Burke et al., Med. J. Aust., (1980), 382-383
Segasouthy et al., Med. J. Malaysia, (1982), 37(4), 384
Ylitalo et al., Acta Med. Scand., (1983), 213, 319-320
Robbins et al., J. Urol., (1983), 130, 975
Adams et al., J. Urol., (1984), 132, 1208
Russell et al., Med. J. Aust., (1985), 143, 321
Taher et al., Int. J. Impotence Res., Abstracts, Milan, Italy (Sep. 14-17, 1992)
Saxena et al., Journal of Medicinal Chemistry, vol. 16, No. 5, 560-564 (1973)
Ishida et al., Chem. Pharm. Bull., vol. 33, No. 8, 3237-3249 (1985)
Gillespie et al., Molecular Pharmacology, 36:773-781 (1989)
Brana et al., Synthetic Communications, 20(12), 1793-1820 (1990)
Dellouve-Courillon et al., Tetrahedron, 46, No. 9, 3245-3266 (1990)
Murray, DN&P 6(3), 150-156 (1993)
Zorgniotti et al. Int. J. Impotence Res., 6, 33-36 (1994